Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00474019 · ClinicalTrials.gov registry record · Phase 1
Phase 1 Pharmacokinetics of Intravenous Nexium in Children
A Phase 1 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 42
- Enrollment target
NCT00474019 is a Phase 1 study that has completed, run by AstraZeneca. The registered enrollment target is 42 participants.
The verdict
NCT00474019, a Phase 1 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 42 participants
- Enrollment target
Study Summary
The purpose of this research study is to evaluate how much of repeated once daily intravenous (IV, meaning through a vein) doses of esomeprazole gets into the bloodstream of hospitalized children aged 0-17 years old that require acid suppression therapy.
Interventions
- DRUG esomeprazole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2007-10 |
| Est. Completion | 2009-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00474019
The ClinicalTrials.gov registry entry for NCT00474019 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which esomeprazole is the first listed.
NCT00474019 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00474019 about?
NCT00474019 is a clinical study titled "Phase 1 Pharmacokinetics of Intravenous Nexium in Children". The purpose of this research study is to evaluate how much of repeated once daily intravenous (IV, meaning through a vein) doses of esomeprazole gets into the bloodstream of hospitalized children aged 0-17 years old that require acid suppression therapy.
What is the current status of trial NCT00474019?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 42 participants. The study started on 2007-10. Estimated completion is 2009-10.
What interventions are being tested in trial NCT00474019?
The interventions under investigation include: esomeprazole (DRUG).
Who is sponsoring clinical trial NCT00474019?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.